Page 258 - EJMO-9-1

Eurasian Journal of
Medicine and Oncology Quality of life, somatosensory amplification, and stress in ADPKD

group was 8.44 ± 5.73 compared with 12.33 ± 6.72 for the between the duration of disease and PSS (r = −0.321,
healthy group, and the difference between these was not p = 0.032), indicating that as the duration of the disease
statistically significant (t = −0.772, p = 0.226) (Table 1). increases, perceived stress decreases. In addition, there
is a significant positive correlation between the duration
Table 2 shows the summary scores of the sub-domains
of HRQOL, including the Physical Component Summary of disease and SSAS (r = 0.255, p = 0.014), suggesting
(PCS) and the Mental Component Summary (MCS). that longer disease duration is associated with higher
Patients with PKD were significantly more likely to have somatosensory amplification. The correlation between
HRQOL and both PSS (r = 0.438, p = 0.622) and SSAS
lower scores in physical functioning (41.81 ± 27.66), (r = 0.408, p = 0.182) was not statistically significant.
physical role (36.39 ± 44.11), general health (43.97 ±
21.82), social functioning (52.14 ± 46.83), and vitality Among the PKD patients (n = 50), the duration of
(41.66 ± 24.62) compared to the healthy group. In addition, disease was negatively correlated with PSS (r = −0.298,
patients with PKD had a significantly lower PCS score than p = 0.013), showing that longer disease duration is linked
the healthy group. However, although the MCS score for to lower perceived stress levels. However, no significant
patients with PKD was lower than that of the healthy group, correlation was found between the duration of disease
this difference was not statistically significant. These results and HRQOL (r = −0.102, p = 0.364) or SSAS (r = 0.864,
indicate that PKD negatively impacts physical functioning p = 0.152). The lack of a simple correlation does not
and general health, but its effect on mental health is not necessarily indicate the absence of an effect. Regression
pronounced. analysis demonstrates that disease duration exerts a
significant negative influence on HRQOL, implying that
In addition, emotional well-being (62.44 ± 28.64), this relationship may be moderated by variables such
emotional role (44.77 ± 18.56), and total MCS scores were as age and gender. A significant positive correlation was
lower than the healthy group, although not statistically found between HRQOL and SSAS (r = 0.286, p = 0.038),
significant (p > 0.05). The patients with PKD had a indicating that higher somatosensory amplification is
significantly higher score for bodily pain (67.71 ± 27.93) associated with better HRQOL scores in this group.
than the healthy group, suggesting that they were more When isolating the effect of somatosensory amplification
troubled by their kidney disease. (SSAS), its impact on HRQOL appears to be negative,
The correlation analysis presented in Table 3 highlights suggesting that SSAS may be associated with poorer
several significant relationships between HRQOL, PSS, HRQOL when considered in the context of other clinical
SSAS, and the duration of disease among all participants and psychological factors. Furthermore, there is a strong
and specifically within the PKD group. For all participants and statistically significant positive correlation between
(n = 98), a significant negative correlation was observed PSS and SSAS (r = 0.692, p = 0.001), suggesting that higher
levels of perceived stress are closely linked to increased
somatosensory amplification.
Table 2. Comparison of HRQOL scores for PKD group and
healthy group These findings emphasize the complex interplay
between psychological and physical factors in PKD. The
Variable PKD group Healthy group p results indicate that while the duration of the disease can
(n=48) (n=50)
Physical functioning 41.81±27.66 74.22±27.81 0.017* influence stress and somatosensory amplification, it does
not significantly impact HRQOL in the same way. The
Physical role 36.39±44.11 62.17±42.55 0.038* strong relationship between PSS and SSAS highlights the
Bodily pain 67.71±27.93 32.46±72.18 0.022* potential importance of psychological interventions in
General health 43.97±21.82 59.27±22.36 0.013* managing the overall HRQOL in patients with PKD. The
Emotional well-being 62.44±28.64 75.12±26.83 0.548 statistically significant correlations at the 0.01 and 0.05
Emotional role 44.77±18.56 58.16±23.17 0.385 levels underscore the reliability of these associations and
Social functioning 52.14±46.83 66.72±35.71 0.050* point to key areas for further research and clinical focus.
Vitality 41.66±24.62 51.18±29.55 0.013* Table 4 presents the effects of the duration of disease
PCS 45.49±26.18 66.52±23.52 0.014* and the level of perceived stress on HRQOL in the PKD
MCS 64.26±27.74 69.48±24.18 0.466 group. In Model 1, the duration of disease showed a
significant negative effect on HRQOL, with a standardized
Note: This table presents the t-test results. *p<0.05. beta coefficient (β) of −0.512 (p = 0.012). This indicates that
Abbreviations: HRQOL: Health-related quality of life; MCS: Mental
component score; PCS: Physical component score; PKD: Polycystic longer disease duration is associated with poorer HRQOL.
kidney disease. The model also showed a moderate level of correlation

Volume 9 Issue 1 (2025) 250 doi: 10.36922/ejmo.7550